Camille L. Bedrosian - Apr 16, 2024 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Medical Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Apr 16, 2024
Transactions value $
$0
Form type
4
Date filed
4/18/2024, 08:19 PM
Previous filing
Nov 29, 2023
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Award $0 +96.9K +166.13% $0.00 155K Apr 16, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Award $0 +120K $0.00 120K Apr 16, 2024 Common Stock 120K $2.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F2 25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.